Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study)
The addition of losartan to mFOLFIRINOX in the AFPAC study did not provide an early signal of efficacy in improving progression-free survival in advanced PDAC. The trial will not proceed to full accrual of phase 3 design.
Authors
- Vikram Chaudhari (ORCID: https://orcid.org/0000-0001-8033-0277)
- Prabhat Bhargava (ORCID: https://orcid.org/0000-0002-6440-2186)
- Shailesh V. Shrikhande (ORCID: https://orcid.org/0000-0002-8036-4212)
- Anant Ramaswamy (ORCID: https://orcid.org/0000-0002-8169-4264)
- Vikas Ostwal (ORCID: https://orcid.org/0000-0002-0067-4748)
- Sarika Mandavkar
- Manish Bhandare (ORCID: https://orcid.org/0000-0002-5390-130X)
- Nowrina Khan
- Khushboo Gandhi (ORCID: https://orcid.org/0000-0002-7439-1417)
- Neha Mer
- Himanshu Gujarathi
- Vikram Gota (ORCID: https://orcid.org/0000-0001-8942-0332)
- Manan Vora
- Noorzia Sultana
- Poonam Jadhav
- Sujay Srinivas
Institutions
- Government Medical College (IN)
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
- Bharath Hospital & Institute of Oncology (IN)
- Advanced Centre for Treatment, Research and Education in Cancer (IN)
Publication Details
- Journal
- Cancer
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1002/cncr.35945
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09